No. This is an intentional accelerated approval. Approved based “likelihood of clinical benefit based on bio marker changes”. The FDA is NOT saying it definitely works, it’s saying there is enough data to give early access.
CMS can do a “Coverage Determination” as they often do and either not cover it at all (unlikely) or severely limit it’s use (likely) potentially to patients who agree to be a part of a registry where outcomes are collected.
